• Friday, 19 March 2021 07:00
    SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

    Three abstracts highlighting the company’s recent research into ocular diseases and its lead gene therapy treatment SPVN06 have been accepted for the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, to be held virtually from 1-7 May. 

  • Tuesday, 16 February 2021 07:00
    SparingVision Conference Participation in H1 2021

    SparingVision announces the conferences that its management team will be participating in in the first half of 2021.

  • Thursday, 04 February 2021 07:00
    Dr. Daniel C. Chung appointed as Chief Medical Officer of SparingVision

    Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development

  • Monday, 01 February 2021 07:00
    Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board

    Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board

  • Thursday, 29 October 2020 08:00
    SparingVision Strengthens Management Team
  • Wednesday, 21 October 2020 07:00
    SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer
  • Tuesday, 30 June 2020 08:00
    SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophies
  • Tuesday, 03 December 2019 07:00
    SparingVision wins First Prize at EIT European Health Catapult competition
  • Thursday, 25 July 2019 08:00
    SparingVision to Present at the Ophthalmology Innovation Summit (OIS) in Chicago on July 25th, 2019 during the American Society of Retinal Specialists (ASRS) meeting
  • Friday, 05 July 2019 08:00
    SparingVision awarded at EIC Accelerator program (H2020 SME instrument Phase 2), securing funding of €2.5 million
  • Thursday, 04 July 2019 08:00
    SparingVision sélectionnée au programme européen EIC Accelerator (H2020 SME instrument Phase 2) pour un financement de 2,5 millions d’euros
  • Thursday, 25 April 2019 08:00
    SparingVision to present preclinical datas for Retinitis Pigmentosa’s treatment during Annual Congress of the Association for Research in Vision and Ophthalmology (ARVO)
  • Tuesday, 26 February 2019 07:00
    Journée Internationale des Maladies Rares
  • Tuesday, 05 February 2019 07:00
    SparingVision récompensée par le « Mercure des Entrepreneurs HEC 2019 » dans la catégorie « Création d’Entreprise »
  • Tuesday, 09 January 2018 07:00
    SparingVision sélectionnée pour une présentation publique au 10e Biotech Showcase™
  • Monday, 08 January 2018 07:00
    SparingVision to Participate in the 10th Annual Biotech Showcase in San Francisco,
  • Wednesday, 12 July 2017 08:00
    1 For Release: July 12, 2017 Contact: Rhea Farberman, Foundation Fighting Blindness 410-423-0635 SparingVision Wins Grand Prize of 2017 i-Lab Contest for New, Innovative French Companies